Polycystic Kidney, Autosomal Dominant Clinical Trial
— TAMEOfficial title:
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
Verified date | August 2022 |
Source | University of Pittsburgh |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will test to see if metformin is safe and if it is tolerated compared to placebo in adult Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients with beginning stages of chronic kidney disease. We will also measure its effect on progression of kidney disease as reflected in the kidney size and the kidney function, along with its effect on kidney pain and quality of life.
Status | Completed |
Enrollment | 97 |
Est. completion date | December 7, 2020 |
Est. primary completion date | December 7, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility | Inclusion Criteria: Subject has Autosomal Dominant Polycystic Kidney Disease; Subject is fluent in English Exclusion Criteria: Subject is not on active military duty; Subject is not currently participating in another clinical trial; Subject's current GFR is not <50 cc/min/1.73m2; Subject does not have diabetes; Subject does not have a systemic disease other than hypertension and PKD; Subject does not have a solitary kidney; Subject does not have an allergy or intolerance to metformin; Subject is not pregnant or lactating or intending to become pregnant within the next three years; Subject does not have an unstable or unclipped cerebral aneurysm; Subject does not have active coronary artery disease; Subject does not have an MRI incompatible device/implant; Subject does not have severe claustrophobia; Subject has not had any solid organ transplant; Subject does not have a Vitamin B12 deficiency; Subject does not currently take any medications that interact with metformin, such as nifedipine, furosemide, cationic drugs (amiloride, ranitidine, triamterene digoxin, procainamide, quinidine, vancomycin, trimethoprim); Subject does not currently take nor has taken (within 2 weeks) the drug tolvaptan (Jynarque or Samsca) |
Country | Name | City | State |
---|---|---|---|
United States | University of Maryland Medical Center | Baltimore | Maryland |
United States | Tufts Medical Center | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Kyongtae Ty Bae, M.D., Ph.D. | Tufts Medical Center, United States Department of Defense, University of Maryland, Baltimore, University of Southern California |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in the Gastrointestinal Symptoms Rating Scale (GSRS) to 24 Months | GSRS is a widely used, validated 15-item questionnaire used to assess GI symptom burden (minimum, maximum: 1, 7, where higher mean score is worse outcome).
Mean change to 24 months, estimated with a repeated measures analysis (baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model. |
Baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months | |
Primary | Drug Tolerability | Tolerability was based on the first visit a participant responded no to the following question "Can you tolerate this dose of study drug the rest of your life?", which was asked at baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months. | Baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months | |
Primary | Rate of Serious Adverse Events (SAE) | Serious adverse events (SAE) occurring from the time a participant signs the informed consent (at the screening visit) until the end of the study, meeting 1 or more of the criteria of: 1) Resulting in death, 2) Non-elective hospitalization, 3) Life threatening (if patient continued on study drug would result in death), 4) Harming or disabling persistently or permanently , 5) Exceeding the nature, severity or frequency of risk described in the protocol or 6) Resulting in congenital anomaly. | 26 months | |
Secondary | Quality of Life Physical Component | Short Form-36 Quality of Life Physical Component Summary (SF-36 PCS) ranges from 0 (worst possible outcome) to 100 (best possible outcome).
Mean change to 24 months, estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model. |
Baseline, 1 month, 3 months and every 3 months thereafter to 24 months | |
Secondary | Quality of Life Mental Component | Short Form-36 Quality of Life Mental Component Summary (SF-36 MCS) ranges from 0 (worst possible outcome) to 100 (best possible outcome).
Mean change to 24 months, estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model. |
Baseline, 1 month, 3 months and every 3 months thereafter to 24 months | |
Secondary | Back Pain Frequency Over the Past 3 Months Since Last Visit | Odds ratio (OR) per month of back pain Often, Usually, or Always (vs. Never, Rarely, Sometimes) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model. | Baseline, 1 month, 3 months and every 3 months thereafter to 24 months | |
Secondary | Estimated Glomerular Filtration Rate (eGFR) | Mean change to 24 months, estimated with a repeated measures analysis (baseline, 2 weeks, 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months) using a linear mixed model. | Baseline, 2 weeks, and 6 weeks, 1 month, 3 months and every 3 months thereafter to 24 months | |
Secondary | Total Kidney Volume From Magnetic Resonance Imaging | Annual percent change of height adjusted and natural log transformed total kidney volume [ln(htTKV)] was estimated with a linear mixed model. | Baseline, 6 months, 12 months, 18 months, 24 months | |
Secondary | Total Kidney Cyst Volume From Magnetic Resonance Imaging | Annual percent change of height adjusted and natural log transformed total kidney cyst volume [ln(htTKCV)] was estimated with a linear mixed model. | Baseline, 6 months, 12 months, 18 months, 24 months | |
Secondary | Liver Volume From Magnetic Resonance Imaging | Annual percent change of height adjusted and natural log transformed liver volume [ln(htLV)] was estimated with a linear mixed model. | Baseline, 6 months, 12 months, 18 months, 24 months | |
Secondary | Liver Cyst Volume From Magnetic Resonance Imaging | Annual percent change of height adjusted and natural log transformed liver cyst volume [ln(htLCV)] was estimated with a linear mixed model. | Baseline, 6 months, 12 months, 18 months, 24 months | |
Secondary | Frequency Abdominal Fullness Interfered With Ability to Perform Usual Physical Activity Over the Past 3 Months Since Last Visit. | Odds ratio (OR) per month of abdominal fullness interfered Often, Usually, or Always (vs. Never, Rarely, Sometimes) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model. | Baseline, 1 month, 3 months and every 3 months thereafter to 24 months | |
Secondary | Interference of Pain With Sleep Over the Past 3 Months Since Last Visit | Odds ratio (OR) per month of pain interfered with sleep Quite a bit or Extremely (vs. Not at all, A little bit, Moderately) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model. | Baseline, 1 month, 3 months and every 3 months thereafter to 24 months | |
Secondary | Interference of Pain With Strenuous Physical Activity Over the Past 3 Months Since Last Visit | Odds ratio (OR) per month of pain interfered with strenuous physical activity Quite a bit or Extremely (vs. Not at all, A little bit, Moderately) estimated with a repeated measures analysis (baseline, 1 month, 3 months and every 3 months thereafter to 24 months) using a generalized linear mixed model. | Baseline, 1 month, 3 months and every 3 months thereafter to 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Completed |
NCT04363554 -
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
Completed |
NCT03687554 -
Effect of Venglustat in Patients With Renal Impairment
|
Phase 1 | |
Terminated |
NCT03523728 -
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00565097 -
Lanreotide as Treatment of Polycystic Livers
|
Phase 2/Phase 3 | |
Completed |
NCT00410007 -
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT02251275 -
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT01559363 -
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02903511 -
Feasibility Study of Metformin Therapy in ADPKD
|
Phase 2 | |
Completed |
NCT00456365 -
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
Recruiting |
NCT05510115 -
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Completed |
NCT02494141 -
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
|
Phase 4 | |
Completed |
NCT04407481 -
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
|
||
Completed |
NCT02847624 -
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
|
||
Completed |
NCT03342742 -
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT04023214 -
The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
|
||
Terminated |
NCT01589705 -
The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
|
N/A | |
Completed |
NCT00426153 -
Octreotide in Severe Polycystic Liver Disease
|
Phase 2/Phase 3 | |
Completed |
NCT04534985 -
Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease
|
N/A |